The introduction of inter partes review (IPR) altered the U.S. patent landscape significantly upon its introduction by the America Invents Act in 2012. Through July 2016, the PTO has received nearly 5000 petitions. While the majority of petitions are directed to patents in the electrical/computer arts, the number of petitions filed against pharmaceutical and biotech patents has almost doubled since 2014.
In this program, presenters Angus Chen and Andrew Wasson, partners at Haug Partners LLP, will survey the use of IPR petitions in the pharmaceutical and biotechnology industries. They will review the basic framework of an IPR proceeding, summarize key pharma and biotech petition decisions, and discuss how recent changes to the rules may affect strategy. They will also consider how IPRs in pharma and biotech factor into other litigation and regulatory strategy decisions. Additionally, the program will include a discussion of other important developments, such as the use of IPR proceedings by non-practicing entities.
Yet another subject I was clueless about before watching. Good presenters.
Great presentation. Thank you.
very helpful presentation